-
Mashup Score: 0Route of Administration for UGN-101 and the Impact on Oncological & Safety Outcomes - Jennifer Linehan - 2 hour(s) ago
Sam Chang engages with Jennifer Linehan to discuss topical chemotherapy for upper tract urothelial carcinoma, particularly utilizing UGN-101 (Jelmyto). Dr. Linehan shares her invaluable insights and experiences, primarily from the OLYMPUS trial, highlighting the evolution in administration methods for UGN-101, transitioning from retrograde to the more convenient antegrade approach via a…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 7APCCC 2024: PSMA Radioligand Therapy – State of the Art - 2 hour(s) ago
APCCC 2024, PSMA Radioligand Therapy, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), PSMA-617, PSMA-1&T, PSMA-1007 rhPSMA-7, 68Ga PSMA-11, VISION trial, TheraP trial, PSMAfore trial, PSMAddition trial, 177Lu-PSMA-617, LuPSMA, SPLASH (NCT04647526) trial,177Lu-PNT2002, LuTectomy trial, ENZA-p (ANZUP 1901), JNJ-69086420, Actinium-225-labeled antibody, human Kallikrein 2, NCT04644770, 68Ga-RM2, somatostatin receptor-2 (SSTR2) PET, SSTR2 PET.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5APCCC 2024: How Do Non-DDR Genomic Alterations Influence Management of Patients with Advanced Prostate Cancer? - 2 hour(s) ago
APCCC 2024, prostate cancer, metastatic castrate-sensitive prostate cancer (mCSPC), non-DNA Damage Response (DDR) genomic alteration, Non-DDR Genomic Alterations, Advanced Prostate Cancer, SWOG2312 trial, RET fusions, selpercatinib, larotrectinib, entrectinib, BRAFV600E, dabrafenib, trametinib, HER2 overexpression, fam-trastuzumab deruxtecan, Microsatellite instability-high (MSI-H), tumor mutational burden high (TMB-H), DNA mismatch repair deficiency (dMMR), pembrolizumab, dostarlimab, positive AR-V7 splice variants, SWOG2312 trial, cabazitaxel, enzalutamide.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4APCCC 2024: Who Should Undergo Germline Testing? - 2 hour(s) ago
APCCC 2024, advanced prostate cancer, germline testing for prostate cancer, metastatic castrate-resistant prostate cancer (mCRPC), germline mutations, BRCA1, BRCA2, ATM, PALB2, CHECK2, HOXB13, MLH1, MSH2, MSH6, PMS2.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 6
The TV personality urges his followers to “please wear sunscreen” after being diagnosed with skin cancer.
Source: www.bbc.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4APCCC 2024: How to Treat Men with Aggressive Variant or Neuroendocrine Prostate Cancer - 3 hour(s) ago
APCCC 2024, Aggressive Variant Prostate Cancer, Neuroendocrine Prostate Cancer, Lurbinectedin, CHAMP trial, valemetostat, Tarlatamab (AMG-757), Cisplatin, etoposide, Carboplatin, Docetaxel, Cabazitaxel, Cisplatin/etoposide, Carboplatin/etoposide, Docetaxel/carboplatin, Cabazitaxel/carboplatin, CXCR2 (C-X-C Motif Chemokine Receptor 2), SYNERGY-201 trial, niraparib plus cetrelimab, delta-like ligand 3 (DLL3), Bispecific T-cell Engager (BiTE®) therapy.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2
The Joint Commission and the National Committee for Quality Assurance will launch updated accreditation programs for telehealth providers.
Source: www.statnews.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 10Boy finds rare Lego octopus on Cornwall beach after 1997 spill - 4 hour(s) ago
The lost Lego piece was one of millions which fell off a cargo ship and into the sea in 1997.
Source: www.bbc.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Behind the Screens: Building Apps for Active Lifestyles - Pedro Wunderlich (Pt1) | Physical Activity Researcher - 5 hour(s) ago
In a recent episode of the “Physical Activity Researcher Podcast,” hosted by Dr. Olli Tikkanen, listeners are taken on a deep dive into the world of app development, entrepreneurship, and the importance of physical activity in daily life. The episode features Pedro Wunderlich, a mobile app designer, serial entrepreneur, and co-founder of the acclaimed Wake N Shake App and React Messenger App. With a track record of over three million app downloads and the backing of prestigious investors, Wunderlich shares his journey from being a young boy with a humor blog to becoming a tech innovator with apps recognized by Apple. Throughout the conversation, Wunderlich emphasizes the significance of physical activity as a core component of his entrepreneurial journey. He candidly discusses the challenges he faced, including battling chronic stress and depression, and how staying physically active became a lifeline for him. This passion for movement eventually led to the creation of Wake Out, an app
Source: paresearcher.podbean.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 6
APCCC 2024 ideal sequence after ADT alone or ADT + ARPI for treatment in the metastatic hormone sensitive prostate cancer (mHSPC) setting, NCCN prostate cancer guidelines,
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Route of administration for #UGN-101 and the impact on oncological & safety outcomes. @Dr_Jen_Linehan @providencesocal and @UroCancerMD @VUMCurology discuss topical chemotherapy for #UTUC particularly utilizing @jelmyto in this discussion on UroToday > https://t.co/9ElulVWo7f https://t.co/744mj3r3kE